Identification of the Benzoimidazole Compound as a Selective FLT3 Inhibitor by Cell-Based High-Throughput Screening of a Diversity Library-Reference-Cited by-同舟云学术

Identification of the Benzoimidazole Compound as a Selective FLT3 Inhibitor by Cell-Based High-Throughput Screening of a Diversity Library

Published:2022-02-11 Issue:4 Volume:65 Page:3597-3605
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Tian Tian¹²,Zhang Shengyi¹³,Luo Bingling¹,Yin Feng¹,Lu Wenhua¹,Li Yiqing⁴,Huang Kezhi⁴,Liu Qiao¹,Huang Peng¹,Garcia-Manero G⁵,Wen Shijun¹^ORCID,Hu Yumin¹^ORCID

Affiliation:

1. State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong 510060, China

2. Department of Medical Biochemistry and Molecular Biology, School of Medicine, Jinan University, Guangzhou, Guangdong 510632, China

3. Department of Oncology, Jiangxi Provincial People’s Hospital, Nanchang, Jiangxi 330006, China

4. Department of Hematology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong 510120, China

5. Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030, United States

Funder

Ministry of Science and Technology of the People's Republic of China

National Natural Science Foundation of China

Guangdong Province

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.1c02079

Reference27 articles.

1. Targeting FLT3 mutations in AML: review of current knowledge and evidence

2. The Presence of FLT3/ITD Mutations Is an Independent Prognostic Factor in Acute Myeloid Leukemia Patients with Normal Karyotype.

3. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials

4. FLT3 inhibitors in acute myeloid leukemia: ten frequently asked questions

5. Inhibition of the MEK/MAPK signal transduction pathway strongly impairs the growth of Flt3-ITD cells

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Innovative medicinal chemistry strategies for enhancing drug solubility;European Journal of Medicinal Chemistry;2024-12

2. Developments of Fms-like Tyrosine Kinase 3 Inhibitors as Anticancer Agents for AML Treatment;Current Medicinal Chemistry;2024-09

3. New Insights into Strategies for Solubility Improvement;2024

4. Effect of N, S atoms on the mechanisms of H‐transfer for five‐membered nitrogen‐containing heterocycles;Journal of Physical Organic Chemistry;2023-11-14

5. Targeting Proliferation Signals and the Cell Cycle Machinery in Acute Leukemias: Novel Molecules on the Horizon;Molecules;2023-01-26